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Abstract Lifestyle factors including diet, body fatness and physical activity modulate the
risk of developing colorectal cancer (CRC) and it is estimated that over half of
CRC cases in the UK are linked to such factors. This review focuses on
describing the underlying mechanisms behind the effects of lifestyle factors
(predominantly dietary) for which there is strong (convincing or probable)
evidence for effects on CRC risk, described in the recently published World
Cancer Research Fund/American Institute for Cancer Research colorectal cancer
report. These include a protective effect of physical activity, wholegrains and
dietary fibre, dairy products and calcium supplements, and increased risk
associated with red and processed meats, alcoholic drinks and higher body
fatness. The postulated mechanisms underlying the effects of lifestyle on CRC
risk, including effects on inflammation, insulin resistance and the microbiome,
and affecting pathways involved in the regulation of cell proliferation,
differentiation, DNA repair and apoptosis are described. Epigenetic mechanisms
that are dysregulated in colorectal carcinogenesis leading to aberrant patterns of
DNA methylation and aberrant expression of microRNAs may also be
modulated by lifestyle factors and consequently modulate CRC risk. It is likely
that an interplay of these mechanisms is involved in the modulation of CRC risk
as well as a combination of these lifestyle factors.
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Introduction
Colorectal cancer (CRC) risk is strongly modulated by
lifestyle factors including diet, physical activity and
body fatness. It has been estimated that 54% of CRC
cases in the UK are linked with such factors, suggest-
ing that a large proportion of cases may be prevented
by adopting a healthier lifestyle (Brown et al. 2018).
The recently published World Cancer Research Fund
(WCRF)/American Institute for Cancer Research
(AICR) report has reviewed the literature (mainly epi-
demiological studies) for evidence for the links
between diet, nutrition, physical activity and cancer,
including CRC (WCRF/AICR 2018). The potential
mechanisms underlying the effects of diet-related
factors, for which WCRF/AICR consider there is
strong evidence (subdivided into ‘convincing’ or
‘probable’ evidence) for an effect on CRC risk
(Table 1), will be the focus of this review. The
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WCRF/AICR report concluded that for CRC there is
convincing evidence for a protective effect of physical
activity, and an increased risk with high intakes of
processed meat and alcohol as well as with increased
body fatness and adult attained height (not discussed
in this review). The evidence that higher intakes of
wholegrains, dietary fibre, dairy products and calcium
supplements are protective was described by WCRF/
AICR as probable.
The mechanisms underlying the effects of lifestyle
factors, including nutrition, on CRC risk are not fully
understood and are likely to include overlapping
mechanisms. As chronic inflammation causes genomic
damage and drives colorectal carcinogenesis, those fac-
tors that induce inflammation, such as obesity and
consumption of certain nutrients, are likely to exacer-
bate CRC risk. This risk may also be modulated via
effects on insulin sensitivity and associated hormones
and growth factors, such as adiponectin and insulin-
like growth factor 1 (IGF-1). More recently, it has
been discovered that the epigenome is modulated by
dietary factors including non-nutrient bioactives
(Mathers et al. 2010). The epigenome is a consortium
of chemical marks (DNA methylation and post-trans-
lational modification of histones) and molecules (e.g.
non-coding RNAs) that regulate gene expression with-
out changes in the gene sequence. In cancers and other
diseases, there are multiple changes in the epigenome,
many of which are causal in the pathogenesis of the
disease. Therefore, altered epigenetic mechanisms play
a role in modulation of CRC risk and this may be an
important mechanism of action of dietary factors. For
example, butyrate [a short-chain fatty acid (SCFA)
product of dietary fibre fermentation] is a well-estab-
lished modulator of histone acetylation and has been
shown to modulate the expression of microRNAs
(miRNAs). The microbiome is also a key player in the
regulation of health and diseases, particularly those in
the gut such as inflammatory bowel disease (IBD) and
CRC. The abundance of individual bacterial and fun-
gal species and the diversity of the gut microbiota are
influenced by lifestyle factors, such as obesity and the
intake of dietary fibre and fatty acids, which may also
modulate CRC risk (Maruvada et al. 2017; Makki
et al. 2018).
Physical activity
The WCRF/AICR panel concluded that there is con-
vincing evidence for lower CRC risk with increased
physical activity (WCRF/AICR 2018). Physical activity
is one of the strongest chemoprotective lifestyle factors
against CRC and observational studies estimate that
14% of CRC cases are attributable to physical inactiv-
ity (Colditz et al. 1997; Samad et al. 2005). However,
there have been no physical activity intervention stud-
ies with CRC as the outcome, and most of the evi-
dence is from observational studies. In the context of
secondary prevention, a systematic review and meta-
analysis of five randomised controlled trials in CRC
patients concluded that there was insufficient robust
evidence to make recommendations on physical activ-
ity in this group (Cramer et al. 2014). In a mouse
model of intestinal tumorigenesis, an exercise interven-
tion comprising running for 1 hour per day for 6 days
per week at a speed of 15 miles per minute (between
the ages of 4 and 16 weeks) was associated with a sig-
nificantly reduced number of large polyps compared
with sedentary mice (McClellan et al. 2014). In a sim-
ilar mouse model of CRC, treadmill running for up to
12 weeks (30–60 minutes per day, 5 days per week)
significantly reduced the number of large intestinal
adenomas and appeared to reduce tumour multiplicity
(Basterfield & Mathers 2010). The authors concluded
that the effects of exercise on intestinal tumorigenesis
may have been mediated by colonic butyrate levels;
whereby the exercised mice had significantly greater
levels of butyrate in colonic digesta and there was a
trend for an inverse relationship between butyrate
molar proportion and the total number of adenomas.
Physical activity may indirectly modulate CRC risk
via its beneficial effects on body fatness (discussed in
the following section on body fatness), and conse-
quently on insulin resistance and inflammation.
Directly, physical activity stimulates digestion and
reduces food transit time and therefore may reduce
the exposure of the large bowel to potential carcino-
gens (Peters et al. 2001). Physical activity may also
Table 1 Strong evidence (convincing or probable) for effects of
diet, nutrition and physical activity on colorectal cancer risk.
Adapted from the WCRF/AICR report (WCRF/AICR 2018)
Decreases risk Increases risk
Strong
evidence
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help to normalise markers that are dysregulated in
CRC. For example, circulating concentrations of insu-
lin, leptin and growth factors (discussed in the follow-
ing section on body fatness) improve with exercise
(Winzer et al. 2011).
Increased concentrations of bile acids in faeces and
serum have been associated with several cancers,
including CRC and other gastrointestinal cancers
(Bayerdorffer et al. 1995; Ajouz et al. 2014), and sig-
nificantly increased faecal bile acids have been
observed in CRC patients (Imray et al. 1992). Second-
ary bile acids are the products of bile acid fermenta-
tion by the gut microbiota and associated with
detrimental effects on the colorectal mucosa including
oxidative DNA damage, reduced DNA repair and
stimulation of cell proliferation and inflammation
(Ajouz et al. 2014; Dossa et al. 2016). The secondary
bile acids, deoxycholic acid and lithocholic acid, and
cholate promote the production of reactive oxygen
species (ROS), which induce DNA damage and subse-
quently genomic instability, which is a hallmark of
cancer (Hanahan & Weinberg 2011; Ajouz et al.
2014). In humans, the evidence for the effects of phys-
ical activity on bile acid levels is limited. In a cross-
sectional study of 735 colorectal adenoma patients,
participants in the highest quartile of recreational
physical activity duration had significantly lower fae-
cal bile acid concentrations than those in the lowest
quartile after adjusting for factors such as age, dietary
fibre intake and BMI (Wertheim et al. 2009). Male
distance runners have lower faecal bile acid concentra-
tions than sedentary individuals but this difference dis-
appeared following adjustment for dietary fibre intake
whereby runners had a greater consumption of dietary
fibre (Sutherland et al. 1991). In 30 healthy individu-
als, running reduced serum concentration of total bile
acids by almost 50% (Danese et al. 2017). These
effects may result from acute reduction in serum
cholesterol, which subsequently limits bile acid synthe-
sis in the liver, and by the modulation of triglyceride
and/or cholesterol levels. In individuals with low
triglyceride concentrations, higher physical activity
reduced faecal bile acids by almost 40% (Wertheim
et al. 2009).
Prostaglandin levels in the colonic mucosa have
been associated with CRC and other cancers (Wang
& Dubois 2006; Wang & DuBois 2013). A study in
63 participants at higher risk of CRC (with a history
of polyps) quantified prostaglandin E2 levels in the
rectal mucosa and observed that leisure time physical
activity (assessed through a self-completed question-
naire) was inversely correlated with prostaglandin E2
concentrations (Martinez et al. 1999). A fivefold
increase in activity levels was associated with almost a
third reduction in prostaglandin E2, suggesting that
this could be another potential mechanism for the
effects of physical activity on CRC risk.
In humans, physical activity has been associated
with multiple beneficial effects on the immune system
including a reduction in senescent T cells, reduced
inflammatory responses and inflammatory cytokine
levels and increased natural killer cell activity (Shep-
hard et al. 1994). However, the effects on the immune
system may vary depending on the type, intensity and
duration of the physical activity (Kruger et al. 2016).
In a mouse model of intestinal tumorigenesis already
described, an exercise intervention resulted in a reduc-
tion in macrophages and regulatory T cells and an
increase in markers of cytotoxic T cells, and this was
associated with a reduced number of large polyps
compared with sedentary mice (McClellan et al.
2014). In a human study, physical exercise may signif-
icantly improve anti-cancer immune function in cancer
survivors (Fairey et al. 2002).
The effects of physical activity on CRC risk may be
mediated via effects on cell proliferation and apoptosis
in the large bowel. In sedentary individuals, a 12-
month intervention of 60-minute moderate-to-vigorous
aerobic exercise 6 days per week resulted in a signifi-
cant reduction in markers of colonic crypt cell prolif-
eration, such as the proportion of proliferating cells in
the upper half of the crypt, in male participants exer-
cising for a minimum of 250 minutes per week
(McTiernan et al. 2006). A trend was also observed
for a greater reduction in cell proliferation with
increasing amounts of exercise. In the same study,
assessment of apoptotic markers revealed a significant
reduction in the pro-apoptotic protein Bax in the base
of the crypts in males, and middle and top of the
crypts in females randomised to the exercise arm
(Campbell et al. 2007).
More recently, the impact of physical activity on
the gut microbiome, and consequently the modulation
of gut health via effects on, for example, inflamma-
tion, has been investigated. The microbiome plays a
key role in maintenance of the healthy mucosa and
adequate gastrointestinal immune function. Distur-
bances in the microbiome may lead to inadequate
immune function and dysbiosis is observed in diseases
such as inflammatory bowel disease (IBD), CRC (Tilg
et al. 2018) and non-gastrointestinal diseases, such as
allergies and asthma (Fujimura & Lynch 2015; Huang
& Boushey 2015). In IBDs, such as ulcerative colitis,
exercise has been shown to improve gastrointestinal
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immune function and the microbiota–immune system;
however, most of the evidence comes from animal
studies and human data are limited (Cook et al.
2016).
Oxidative stress and the generation of ROS and free
radicals may promote colorectal carcinogenesis. The
high cell turnover and metabolic rate of colorectal
epithelial cells make them particularly vulnerable to
damage by ROS and oxidative stress. DNA damage in
these cells, particularly proliferating cells, can result in
replicative errors and genomic instability and mutage-
nesis (Saha et al. 2017). Improvements in antioxidant
capacity with physical activity via effects on signalling
pathways such as MAPK and NFΚB, which have been
shown to be activated with exercise in both humans
and animal models, result in protection of cells against
free radicals and ROS (Perse 2013).
Body fatness
Obesity is a well-established risk factor for CRC and
a systematic review of prospective studies, including
approximately 9 million participants, reported a 33%
increase in CRC risk in obese individuals compared
with those with a normal BMI (Ma et al. 2013). Fur-
thermore, individuals with a large waist circumference
had a 46% increased risk of CRC (Ma et al. 2013). In
a meta-analysis including over 50 000 CRC cases, the
increases in CRC risk associated with weight, BMI
and waist circumference (a marker of central adipos-
ity) were 2% (per 5 kg increase in weight), 6% (per
5 kg/m2 increase in BMI) and 2% (per 10 cm increase
in waist circumference), respectively (Abar et al.
2018). A meta-analysis of 30 prospective studies con-
cluded that the effects of obesity on CRC risk are
dependent on sex and cancer site (Larsson & Wolk
2007). In both males and females, increased waist cir-
cumference and waist–hip ratio were associated with a
significant increase in colon cancer risk. Thirty percent
and 12% increased risk of colon cancer was observed
with a 5-unit increase in BMI in males and females,
respectively; however, an effect of BMI on rectal can-
cer risk was observed only in males.
Obesity is associated with chronic low-grade sys-
temic inflammation, which is perhaps the primary
mechanism associated with increasing CRC risk. CRC
is an inflammatory disorder and chronic inflammation,
such as that observed in patients with IBD, is associ-
ated with increased CRC risk (Kim & Chang 2014).
This risk rises with disease duration: CRC risk may be
increased by almost 20% in patients with >30 years
of inflammatory disorders (Eaden et al. 2001). The
chronic low-grade inflammation induced by obesity,
evidenced, for example, by increased expression of
inflammatory markers such as C-reactive protein
(CRP) and interleukins (e.g. IL-6), is therefore likely
to be a key mechanism (Ellulu et al. 2017). Raised
CRP concentrations have been associated with CRC
risk and incidence (Mazhar & Ngan 2006). With
increased adiposity, there is an increase in pro-inflam-
matory molecules secreted from adipocytes and
macrophages that reside in white adipose tissue.
Tumour necrosis factor-a (TNF-a) is a pro-inflamma-
tory cytokine that is constitutively expressed by adipo-
cytes and therefore contributes to the stimulation of
an inflammatory state associated with obesity, and this
correlates positively with BMI (Hotamisligil et al.
1993). Inflammation may also exacerbate the obesity-
induced insulin resistance; for example, the inflamma-
tory cytokines (e.g. IL-6) may disrupt insulin signalling
(Shoelson et al. 2006).
Another potential mechanism relates to the effects
of insulin resistance and regulating hormones such as
insulin and adipokines. Insulin resistance describes the
inability of cells to respond to insulin concentrations,
resulting in increased blood levels of insulin (hyper-
insulinaemia) being required to regulate glucose con-
centrations (Gunter & Leitzmann 2006). Insulin
resistance results from an increase in blood levels of
free fatty acids, resistin and TNF-a, and a reduction in
adiponectin release by adipose tissue (illustrated in
Fig. 1). There is an overlap between risk factors for
the development of insulin resistance and for CRC,
such as surplus energy intake, physical inactivity, a
low-fibre diet (Weickert & Pfeiffer 2018) and body
fatness, providing a plausible mechanism underlying
the effects of such lifestyle and dietary factors on the
risk of developing CRC. Chronically elevated insulin
levels (hyperinsulinaemia) have been associated with
cancers, including CRC and breast cancer. Further-
more, patients with other diseases associated with
insulin resistance, such as metabolic syndrome and
type 2 diabetes mellitus, have a raised risk of develop-
ing CRC (Stocks et al. 2011; Deng et al. 2012). Insu-
lin resistance is associated with increased levels of
insulin, glucose, triglycerides and non-esterified fatty
acids. The resulting hyperinsulinaemia has been associ-
ated with induced colonic epithelial cell growth and
inhibited apoptosis, which animal and human studies
suggest may promote tumour development (Keku
et al. 2005; Tran et al. 2006).
The effects of insulin may result directly, or may be
consequences of, the effects on hormones such IGF-1
and sex hormones such as estrogens (Calle & Kaaks
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2004). It is likely that these mechanisms are simulta-
neously in play to varying extents. It is the induction
of cell proliferation and inhibition of apoptosis in
colorectal mucosal cells that may be the predominant
mechanism behind the effects of the altered levels
of these circulating factors, an excess of which
promotes tumorigenesis in colonocytes and leads to
dysregulation of signalling pathways, such as the
MAPK pathway. In addition, peroxisome proliferator-
activated receptors (PPARs) that are present in the
colorectum may be impaired by these molecules, such
as triglycerides, consequently altering the regulation
of processes such as inflammation, homeostasis,
differentiation, proliferation and apoptosis (Yehuda-
Shnaidman & Schwartz 2012). There is evidence for
protective effects of PPAR-gamma in inhibiting prolif-
eration of colorectal tumours in mice, and reduced
PPAR-alpha expression and protein levels have been
reported in human neoplastic, compared with non-
malignant human colorectal mucosa (Jackson et al.
2003).
Furthermore, an increase in glucose and fatty
acids leads to metabolic dysregulation, oxidative
stress and effects in pathways implicated in carcino-
genesis, which together may promote carcinogenesis
(Gunter & Leitzmann 2006). The production of
ROS and DNA damage coupled with a reduction in
antioxidants resulting from adiposity and
hyperglycaemia and the associated surplus energy is
another mechanism for the effects of obesity on
colorectal carcinogenesis (Gunter & Leitzmann
2006).
In obese individuals, the levels and bioactivity of
free insulin-like growth factor 1 (IGF-1) are increased
(Frystyk et al. 1995; Nam et al. 1997). IGF-1 concen-
trations have been associated with increased risk of
CRC as well as adenomas, precursors to CRC, which
may result from the anti-apoptotic effects of IGF-1
(Vigneri et al. 2015). Insulin and IGF levels, coupled
with a reduction in IGF-binding protein (IGFBP), that
are raised with insulin resistance, promote cellular
proliferation and differentiation (Giovannucci 2001).
The majority of the evidence for this comes from stud-
ies in patients with acromegaly, a hormonal disorder
associated with excess production and secretion of
growth hormone by the pituitary gland, who have
increased epithelial cell proliferation (Cats et al. 1996)
and a greater CRC incidence (Jenkins et al. 2002;
Renehan et al. 2003).
Leptin and adiponectin, two adipocytokines secreted
by adipose tissue, are implicated in colorectal carcino-
genesis. BMI is inversely correlated with circulating
levels of adiponectin, an insulin-sensitising hormone
that regulates intracellular signalling pathways such as
adenosine monophosphate-activated protein kinase
(AMPK) and mammalian target of rapamycin (mTOR)
(Sugiyama et al. 2009). In a case–control study,
plasma adiponectin was inversely correlated with CRC
risk in men, and participants in the highest quintile
had a 60% lower CRC risk compared with those in
the lowest quintile (Wei et al. 2005). On the other
hand, leptin concentrations increase with increasing
BMI and body fatness (Sauter et al. 2004; Ruhl et al.
2007; Paul et al. 2011), and it is overexpressed in
CRC and implicated in cancer initiation and progres-
sion (Koda et al. 2007). The effects of adiponectin
and leptin on CRC risk may result from the inhibition
of apoptosis and the promotion of cell proliferation
(Aparicio et al. 2005; Ogunwobi & Beales 2007;
Fenton & Birmingham 2010; Nigro et al. 2018).
Adiponectin and leptin may also modulate CRC risk
via effects on inflammation (Sitaraman et al. 2004;
Ouchi & Walsh 2007; Drew 2012); for example, adi-
ponectin has been shown to modulate the expression
of genes involved in chronic inflammation and tumori-
genesis (Saxena et al. 2012).
Adiposity and obesity may also affect levels of ster-
oid hormones, such as androgens and estrogens, which
Figure 1 Obesity-induced insulin resistance and the promotion of tumour
development. Reproduced with permission (Calle & Kaaks 2004). FFA, free
fatty acids; IGF-1, insulin-like growth factor-1; IGFBP1, insulin-like growth
factor-binding protein 1; IGFBP2, insulin-like growth factor-binding protein 2;
IGF1R, insulin-like growth factor-1 receptor; IR, insulin receptor; TNF-a,
tumour necrosis factor-a. [Colour figure can be viewed at wileyonlinelibrary.
com]
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may consequently modulate CRC risk. BMI correlates
positively with the estrogens estrone and estradiol
(Schairer et al. 2016). Increased sex hormones may
also result from obesity-induced insulin resistance,
whereby sex hormone-binding globulin (a glycoprotein
that binds androgen and estrogen) synthesis is inhib-
ited by and is inversely correlated with IGF-1
(Pasquali et al. 1995; Daka et al. 2013). Increased
bioavailability of testosterone and estradiol in females
may also result from a reduction in sex hormone-bind-
ing globulin, which in turn is a consequence of adipos-
ity and increased circulating insulin and IGF-1.
The microbiota profile of obese individuals is differ-
ent compared with healthy individuals, including an
increase in bacteria such as the Firmicutes species and
a reduction in Bacteroidetes (Wolf & Lorenz 2012).
Recent research suggests that the gut microbiome is
associated with wide effects on health and disease,
including gastrointestinal health and the risk of dis-
eases such as IBD and CRC (Tilg et al. 2018; Valdes
et al. 2018). Levels and altered diversity of the gut
microbiota (dysbiosis) may be modulated by dietary
factors, such as dietary fibre intake (discussed in the
following section on wholegrains and dietary fibre),
and consequently may have health-promoting effects,
such as an increase in SCFA production, reduction in
gut inflammation, improved insulin sensitivity and
increased antioxidant production. Obesity itself is
associated with a change in microbiota composition
(Turnbaugh et al. 2009) [e.g. a greater ratio of Firmi-
cutes to Bacteroidetes (Ley et al. 2006)], which, in
turn, may promote diet-induced obesity. The potential
effects of microbiota dysbiosis on obesity and disease
risk have been suggested to result from mechanisms
such as the dysregulation of gut hormones, inflamma-
tion and abnormal energy regulation (Valdes et al.
2018). Due to the key role of inflammation in colorec-
tal carcinogenesis, the promotion of low-grade inflam-
mation by microbiota dysbiosis is an important
mechanism for the effects on CRC risk. It is likely to
be the simultaneous effects of the gut microbiome
itself and its metabolic products which collectively
influence CRC risk (Louis et al. 2014).
Wholegrains and dietary fibre
Dietary fibre is found in wholegrains, which include
germ, endosperm and bran as well as vitamins, miner-
als and phytochemicals, and other foods such as fruit,
vegetables and pulses (Jacobs et al. 1998). The obser-
vation of a probable chemoprotective effect of dietary
fibre on CRC was originally proposed in the 1970s by
Dr. Burkitt who observed low CRC rates in Western
Africans whose habitual diet was very high in dietary
fibre (Burkitt 1971). A more recent systematic review
and meta-analysis of 25 prospective studies found
inverse associations between intakes of dietary fibre
and wholegrains, and CRC risk (Aune et al. 2011). In
a meta-analysis of 20 studies including over 10 000
colorectal adenoma patients, a 28% reduction in the
risk of adenomas was associated with a daily 10 g
increase in intake of dietary fibre (Ben et al. 2014). In
the European Prospective Investigation into Cancer
(EPIC) study, an inverse relationship between dietary
fibre intake and CRC incidence was observed, leading
the authors to conclude that doubling dietary fibre
intake could reduce the number of CRC cases by 40%
(Bingham et al. 2003). Higher total intake of whole-
grains, found in foods such as wholegrain breads, oat-
meal, breakfast cereals and brown rice, was associated
with an 18% reduction in risk of colon but not rectal
cancer, and per daily increment of three servings,
CRC risk was reduced by 17% (Aune et al. 2011).
For some time, it has been suggested that both
wholegrains and dietary fibre may reduce CRC cancer
risk by reducing exposure of the lining of the large
bowel to carcinogens by increasing faecal bulk, and
consequently diluting carcinogens and reducing transit
time (Burkitt et al. 1972; Lipkin et al. 1999). In addi-
tion, they contain bioactives, such as polyphenols,
which could have anti-carcinogenic effects, as well as
their fermentation products (i.e. SCFAs).
Epigenetic mechanisms, such as DNA methylation,
may underpin the effects of dietary and other environ-
mental factors on disease risk due to their role in the
aetiology of many diseases including cancers such as
CRC (Huang et al. 2011; Lao & Grady 2011; Sch-
nekenburger & Diederich 2012). Folic acid is found in
wholegrains and there is the suggestion that folate sta-
tus may influence CRC risk (Mathers 2009). However,
the evidence linking folate to CRC is complex and
studies have reported contradicting results. Therefore,
the WCRF/AICR concluded that the evidence for the
effects of folate on CRC risk is ‘limited–no conclu-
sion’ (WCRF/AICR 2018). Due to its role in one-car-
bon metabolism, folate modulates levels of DNA
methylation, consequently gene expression and activity
of signalling pathways. Abnormal DNA methylation is
observed in CRC, including reduced global DNA
methylation levels (hypomethylation) and hypermethy-
lation of tumour suppressor genes, leading to inactiva-
tion of these genes (Baylin 2005). In particular,
hypermethylation and loss of Wingless/Integrated
(WNT) pathway inhibitors have been observed
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(Galamb et al. 2016). The WNT signalling pathway is
involved in the regulation of homeostasis and large
bowel health via effects on processes such as cell pro-
liferation, differentiation and apoptosis but is aber-
rantly activated in CRC. SFRP1, a WNT antagonists,
is hypermethylated in CRC (Caldwell et al. 2004) and
SFRP1 methylation has been observed to correlate
positively with red blood cell folate concentration
(Wallace et al. 2010). Associations between plasma
and red cell folate have also been observed, whereby
these correlated positively with SFRP1 methylation, as
well as additional WNT inhibitors SFRP2 and WIF1,
in healthy individuals (Tapp et al. 2013). These find-
ings support the notion that folate may induce DNA
methylation due to its role as a methyl group donor
(Niculescu & Zeisel 2002).
Wholegrains may indirectly influence CRC risk via
effects of their bioactive content. For example, some
wholegrains are a source of selenium and there is
some evidence linking selenium to a reduced risk of
CRC (Clark et al. 1996; Connelly-Frost et al. 2009).
However, the WCRF/AICR concluded that this evi-
dence is ‘limited–no conclusion’ and further studies
are required (WCRF/AICR 2018). The proposed
underlying mechanisms relate to selenoproteins, which
are involved in the maintenance of homeostasis within
the large bowel via the regulation of pathways and
responses such as the inflammatory response. Meplan
and colleagues identified 254 genes and 26 proteins
implicated in cancer, immune function, inflammation,
cell growth, proliferation, cellular movement and cell
death that showed differential expression in the rectal
mucosa from healthy participants with higher and
lower selenium status (Meplan et al. 2016).
Butyrate is a SCFA produced from the fermentation
of dietary fibre, in particular those with low fer-
mentability, in the large bowel. The literature suggests
that butyrate plays a role in the mediation of lower
CRC risk resulting from higher dietary fibre and
wholegrain intake, perhaps due to its anti-inflamma-
tory properties (Bultman 2014). In addition, butyrate
may modulate CRC risk via its effects on epigenetic
mechanisms and is one of the earliest identified epige-
netic modifiers (Candido et al. 1978). Primarily, buty-
rate is a histone deacetylase inhibitor (HDACi).
HDACis promote gene expression by inhibiting the
removal of acetyl groups from histones, which
facilitates access by the transcriptional machinery due
to a more open chromatin structure (Kurdistani et al.
2004). Another epigenetic mechanism modulated by
butyrate is the expression of miRNAs. We have shown
that in the macroscopically normal colorectum of
healthy participants, supplementation with non-diges-
tible carbohydrates (a source of butyrate) for 7 weeks
significantly increased the expression of miR-32,
involved in the regulation of cell proliferation levels
(Malcomson et al. 2017b). Furthermore, resistant
starch significantly reduced the expression of CTNNB1
and c-MYC, as well as SFRP1, suggesting further
protective effects of dietary fibre via effects on WNT
signalling (Malcomson et al. 2017a).
Dairy products
The WCRF/AICR panel concluded that there is proba-
ble evidence for a reduction in CRC risk with
increased dairy product consumption (WCRF/AICR
2018). The majority of the evidence on dairy products
and CRC comes from observational studies and, to
date, there have not been any randomised controlled
trials. The potential effects of dairy on CRC risk are
likely to result from the content of nutrients such as
vitamin D and calcium (discussed in the following sec-
tion), and butyrate. The anti-cancer properties of
butyrate, which is also found in the milk of most ani-
mals as well as produced in the colon by the micro-
biome, have been described earlier.
Vitamin D has been associated with effects on many
cellular processes implicated in carcinogenesis, includ-
ing cell proliferation, differentiation and angiogenesis.
However, the WCRF/AICR have concluded that the
evidence for the relationship between vitamin D and
CRC is ‘limited–suggestive’ (WCRF/AICR 2018). This
is because, although the evidence for vitamin D was
generally consistent, including in relation to foods con-
taining vitamin D and vitamin D supplements, and
dose–response meta-analyses showed significantly
decreased CRC risk, the number of studies and quality
of evidence are limited. Furthermore, no significant
associations have been observed between plasma/serum
vitamin D concentrations and CRC risk. The potential
effects of vitamin D were first proposed in the 1980s
by Garland et al. who observed a significant threefold
reduced risk of colon cancer in individuals with
25-hydroxyvitamin D (25OHD) concentrations (a mar-
ker of vitamin D status) of 20 ng/ml and above (Gar-
land et al. 1989). Individuals with 25OHD
concentrations between 33 and 41 ng/ml had an 80%
lower risk of colon cancer. Vitamin D may have anti-
inflammatory effects, which could play an important
role in any health-promoting effects in the large bowel.
Furthermore, higher vitamin D status has been associ-
ated with reducing the risk of IBDs such as ulcerative
colitis and Crohn’s disease (Ananthakrishnan et al.
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2012). Approximately a third of IBD patients were
reported to be vitamin D-deficient (plasma 25OHD
concentrations <20 ng/ml) and, at a median follow-up
of 11 years, the deficient patients were at a signifi-
cantly increased risk of cancers particularly CRC
(Ananthakrishnan et al. 2014). It has been suggested
that the beneficial effects of vitamin D on IBD are
likely to be mediated via effects on the immune system
(Ardesia et al. 2015). The possible chemoprotective
properties of vitamin D include its ability to reduce cell
proliferation, induce cell differentiation and apoptosis,
inhibit angiogenesis and regulate miRNA expression
(Fedirko et al. 2009; Alvarez-Diaz et al. 2012; Padi
et al. 2013).
Vitamin D has been shown to inhibit WNT sig-
nalling, a pathway frequently hyperactive in both spo-
radic and inherited CRC cases (described in the
section on wholegrains and dietary fibre). Several
potential mechanisms for the modulation of WNT sig-
nalling by vitamin D have been described (Pendas-
Franco et al. 2008). The active metabolite of vitamin
D, 1,25OH2D3, increases the expression of Dickkopf
1 (DKK-1), which is a WNT pathway antagonist.
Interestingly, DKK1 has been reported to be hyperme-
thylated and consequently transcriptionally silenced in
CRC cell lines (Aguilera et al. 2006). Another member
of the Dickkopf family, DKK-4, is up-regulated in
colorectal tumours and is reduced by 1,25OH2D3
(Matsui et al. 2009).
Other dairy product components that may contribute
to the effects of dairy on CRC risk include folate,
found in cows’ milk (5–10 lg per 100 g) and cheese
(up to 100 lg per 100 g), growth factors and calcium.
The WCRF/AICR panel found consistent evidence for a
decreased risk of CRC with higher consumption of
dietary calcium, found in dairy products, and con-
cluded that taking calcium supplements ‘probably’
protects against CRC (WCRF/AICR 2018). The mecha-
nisms underlying the protective effects of calcium
include its binding to bile and free fatty acids and
effects on cell proliferation and differentiation
(described in the following section on calcium supple-
ments). Mammalian milk also contains the growth
factors IGF-1 and -II, which, as discussed in the section
on body fatness, may affect CRC risk via effects on cell
proliferation and apoptosis. Lactoferrin is a glycopro-
tein found in milk. In vitro and animal studies suggest
chemoprotective properties of lactoferrin, including
inducing apoptosis and reducing inflammation (Ye
et al. 2014; Jiang & Lonnerdal 2017). In a randomised
controlled trial in 104 participants at greater risk of
CRC (with adenomatous polyps), supplementation
with 3 g/day bovine lactoferrin for 12 months signifi-
cantly delayed adenomatous polyp growth (Kozu et al.
2009). However, this effect was only observed in those
aged 63 years or younger. In CRC patients, the clinical
outcomes of treatment with lactoferrin supplementa-
tion plus chemotherapy did not differ significantly from
those observed with chemotherapy only (Moastafa
et al. 2014).
Dairy products contain fats, particularly triglyc-
erides and fatty acids, as well as fat-soluble vitamins
including A, D, E and K, albeit in low amounts in
products such as milk. Evidence from in vitro studies
suggests that the lipids butyric acid and conjugated
linoleic acid present in dairy may inhibit proliferation
and the induction of differentiation (Jass 1985; Sakata
et al. 1995; Kien et al. 2006). In rats, conjugated
linoleic acid is protective against the formation of
azoxymethane-induced aberrant crypt foci by approxi-
mately 20% (Kohno et al. 2002). These effects were
associated with a reduction in proliferation and
induced apoptosis. Microbes in fermented dairy prod-
ucts may have beneficial effects in the colorectal
epithelium that are protective against damage to col-
orectal cells and consequently CRC development. For
example, Lactobacillus bulgaricus found in fermented
dairy products such as yogurt may protect colorectal
epithelial cells by directly binding their apical surface
(Sengupta et al. 2013). In animal models, Bifidobacte-
ria is protective against the development of precursor
lesions to CRC, aberrant crypt foci (Challa et al.
1997).
Calcium supplements
Observational and epidemiological studies suggest a
protective effect of calcium supplements on the risk of
cancers, including CRC, and the WCRF/AICR con-
cluded that the evidence for the effects of calcium sup-
plements at a dose of >200 mg per day on CRC is
probable (WCRF/AICR 2018). In a Korean case–con-
trol study, comprising 922 CRC cases, significantly
reduced CRC risk was observed with the highest cal-
cium intake quartile [odds ratio (OR) 0.16] (Han
et al. 2015). However, randomised controlled trials
have not been able to replicate these findings
(Wactawski-Wende et al. 2006; Bristow et al. 2013).
Supplementation of over 26 000 post-menopausal
women as part of the Women’s Health Initiative with
1000 mg/day elemental calcium was not significantly
associated with an effect on CRC incidence compared
with participants assigned to placebo (Wactawski-
Wende et al. 2006). In the Calcium Polyp Prevention
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Study group, a randomised controlled trial which sup-
plemented 930 individuals with a recent history of
polyps with 3 g calcium carbonate daily or placebo, a
15% reduction in risk of recurrent adenomas (precur-
sors of colorectal cancers) was observed in the calcium
group (Baron et al. 1999). It has been speculated that
calcium may exert a chemoprotective effect by reduc-
ing the cytotoxicity of faecal water, decreasing faecal
bile acids and secondary bile acid concentrations by
binding to these and forming ‘calcium soaps’ (Lam-
precht & Lipkin 2001). Calcium has been proposed to
counteract the effects of dietary fat on increasing
levels of fatty acids in the large bowel by producing
insoluble soaps, thereby counteracting the pro-tumori-
genic effects of fat exposure (Newmark et al. 1984).
Calcium has also been associated with reducing cell
proliferation and promoting differentiation. In the
study by Fedirko and colleagues, described in the sec-
tion on dairy products, expression of p21 (a marker of
cell differentiation) increased by 201% in colorectal
crypts of participants supplemented with calcium for
6 months compared with placebo (Fedirko et al.
2009). The study also analysed effects of the interven-
tion on markers of proliferation and, although there
were no significant effects of calcium supplementation
on MIB-1 expression, a trend for a 10% reduction in
human telomerase reverse transcriptase labelling
compared with placebo was reported. However, the
evidence on the protective effects of calcium supple-
mentation on colonic crypt cell proliferation has
yielded conflicting results (Gregoire et al. 1989; Stern
et al. 1990; Cats et al. 1995; Bostick 1997; Cascinu
et al. 2000). In individuals at increased risk of CRC
(first-degree relatives of patients with hereditary non-
polyposis CRC), calcium supplementation (in the form
of 1.5 g calcium carbonate) three times per day for
12 weeks significantly reduced epithelial cell prolifera-
tion by almost 50% compared with baseline (Cats
et al. 1995). However, these effects did not differ sig-
nificantly to those observed in the placebo group who
received cellulose and starch. In a similar study in
patients with familial polyposis, 1.2 g of calcium daily
for 9 months significantly reduced rectal cell prolifera-
tion levels at 6 months but did not differ significantly
to baseline at the end of the study (9 months) (Stern
et al. 1990). In a trial that supplemented with a
greater dose of calcium (2000 mg/day) for 4 weeks,
calcium supplementation reduced rectal cell prolifera-
tion (Wargovich et al. 1992). It may be that the effects
of calcium on colonic crypt cell proliferation result
from the binding of fatty acids and bile acids (Cats
et al. 1995).
Red and processed meats
According to WCRF and AICR, the evidence for the
associated increased risk of CRC with intake of pro-
cessed and red meats is ‘convincing’ and ‘probable’,
respectively (WCRF/AICR 2018). In the EPIC study,
involving just under 500 000 participants, a 35%
increase in the risk of CRC was observed in partici-
pants with a high red and processed meat intake, clas-
sified as >160 g per day (Norat et al. 2005). However,
in the UK, the National Diet and Nutrition Survey
Rolling Programme for Years 5 and 6 (2012–2014)
found that the mean consumption of red (includ-
ing processed) meat in adults aged 19–64 years was
52 g/day for women and 83 g/day for men (Bates
et al. 2016).
A meta-analysis of 28 prospective studies concluded
that a 14% increase in CRC risk was associated with
each 100 g daily increase in total red and processed
meat intake (Chan et al. 2011). The relative risk (RR)
for processed meat was higher than that observed for
fresh red meat (RR 1.18 vs. 1.17 per 50 g/day and
100 g/day, respectively). A high red meat intake (char-
acterised by a high saturated fat content) may also
modulate CRC cancer risk indirectly via effects on
body fatness (discussed earlier) (Vergnaud et al.
2010). Linked with this, evidence exists for an
increase in the risk of type 2 diabetes with the highest
red and processed meat intake by 21% and 41%,
respectively, compared with individuals with the low-
est intakes (Aune et al. 2009). People with type 2 dia-
betes are at significantly increased risk of developing
CRC by approximately 27% compared with those
without this condition, proposed to result from effects
similar to those related to increased body fatness, such
as insulin resistance, inflammation and alterations to
the microbiome (Gonzalez et al. 2017).
The effects of red meat on CRC risk have been sug-
gested to result from the mutagenic and carcinogenic
compounds found in red meat or produced as a conse-
quence of cooking [e.g. heterocyclic amines (HCAs)
and polycyclic aromatic hydrocarbons (PAHs) from
cooking at a high temperature] (Cross et al. 2003).
High concentrations of haem are found in red meat
and this has also been associated with processes that
may increase CRC risk (Bastide et al. 2011). For
example, in vitro studies have shown that meat haem
proteins catalyse lipid peroxidation and oxidation,
which produce carcinogenic compounds such as
malondialdehyde and also increase oxidative stress
(Carlsen et al. 2005; Papuc et al. 2017). N-nitroso
compounds, found in processed meats such as bacon
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and ham and produced during the curing process
(Lijinsky 1999), are mutagens and carcinogens formed
by N-nitrosation of haem, amines or amides in the
large bowel (Bingham et al. 1996; Cross et al. 2003;
Zhu et al. 2014). Another potential mechanisms for
the role of red meat in CRC risk include its effect of
increasing bile acids (Aykan 2015), which are associ-
ated with induced cell proliferation (discussed in the
earlier sections on physical activity and calcium
supplements).
More recent is the discovery that miRNAs (small,
non-coding RNAs that regulate gene expression and
consequently affect numerous cellular processes, such
as cell proliferation and apoptosis) may play a role in
carcinogenesis. Red meat has been shown to modulate
the expression of miRNAs, in particular the oncogenic
cluster miR-17-92, also known as oncomir-1, which
has been shown to play a role in proliferation, angio-
genesis, differentiation and cell survival (Humphreys
et al. 2014). In a randomised crossover study, a very
high red meat diet (300 g/day lean red meat) for
4 weeks significantly increased levels of members of
the oncomir-1 cluster, such as miR-19a, miR-19b and
miR-21, by approximately a third in the rectal mucosa
of healthy participants. Effects on miRNA expression
were associated with an increase in cell proliferation
and a reduction in the expression of target genes such
as the cell-cycle inhibitor CDKN1A and two pro-
apoptotic genes PTEN and BCL2L11. The findings
from this study suggest cancer-promoting effects of
red meat on expression of the oncogenic miR-17-92
cluster in situ in healthy participants. It must be noted
that the dose of red meat given was very high (300 g
per day) whereas the WCRF/AICR recommend con-
suming no more than 500 g per week (equating to
71 g/day, which is similar to the average consumption
in the UK).
Alcohol
Associations between different levels of alcohol con-
sumption and CRC have been reported: chronic alco-
hol drinking has been associated with increased risk of
CRC, among other cancers, particularly those occur-
ring in the gastrointestinal tract. A recent systematic
review and meta-analysis of 24 studies investigating
the effects of alcohol on CRC incidence reported that
alcohol intake, including light drinking (<12.5 g/day
alcohol), was associated with an overall 13% increase
in CRC risk compared with non/occasional drinking
(Wang et al. 2015). Even light drinking was associated
with a significant increase in CRC risk, albeit by 7%,
and heavy drinking (more than 50 g/day alcohol) with
a 37% increased risk.
A summary of the promotion of carcinogenesis by
alcohol is summarised in Figure 2 (Seitz & Stickel
2007) and will be discussed in the context of CRC
within this section. These effects result predominantly
from metabolites of alcohol, such as the acetaldehyde,
which has carcinogenic properties. Regarding cancer
risk, in the healthy cell, alcohol and its metabolites
are associated with the generation of ROS and DNA
damage (Wu & Cederbaum 2003). It also promotes
cell proliferation, affects DNA methylation and
impairs the immune function, all mechanisms that
have been associated with promoting carcinogenesis.
A strong candidate behind these carcinogenic effects is
acetaldehyde, a metabolite of ethanol that is a group 1
carcinogen. Concentrations of this carcinogen in the
gut are affected by levels of the microbiota or by Heli-
cobacter pylori and by enzymes that metabolise etha-
nol to acetaldehyde (Na & Lee 2017). In turn, alcohol
itself may have effects on the microbiome and conse-
quently promote increased levels of acetaldehyde.
Similar to the potential mechanism suggested for
carcinogenic properties and effects of red and pro-
cessed meats described above, alcohol metabolism pro-
duces pro-carcinogens such as nitrosamines and
polycyclic hydrocarbons via metabolism by CYP2E1
(Poschl & Seitz 2004). Acetaldehyde may cause DNA
damage by hindering DNA repair and oxidative
capacity, for example by binding and altering enzymes
such as O6-methylguanine methyltransferases and glu-
tathione (Seitz & Stickel 2007). DNA damage may
also result from DNA adducts formed directly by
binding of acetaldehyde and due to an increase in
ROS (Seitz & Stickel 2007).
Although other mechanisms induced by alcohol may
play a more important role in other cancers, the
underlying mechanism for the effects of alcohol on
CRC might be its modulation of folate metabolism –
for example, oral alcohol ingestion has been shown to
acutely reduce serum folate levels in humans (Eichner
& Hillman 1973) – and relevant effects on DNA
methylation (Boffetta & Hashibe 2006). Alcohol has
further effects on DNA methylation indirectly by
reducing folate (Halsted et al. 2002), consequently
leading to aberrant expression of genes implicated in
carcinogenesis (Na & Lee 2017). Alcohol may also
alter DNA methylation by inhibiting enzymes such as
those involved in one-carbon metabolism and DNA
methyltransferases, resulting in a reduction in the
methyl donor S-adenosylmethionine (Varela-Rey et al.
2013). Methylation of genes implicated in CRC,
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including the WNT pathway member and tumour
suppressor adenomatous polyposis coli (APC) and
O6-methylguanine-DNA methyltransferases (MGMT),
a gene frequently hypermethylated in CRC, was inves-
tigated in 122 patients with sporadic CRC (van
Engeland et al. 2003). Individuals with a high alcohol
intake (and low folate intake) had increased promoter
hypermethylation of these CRC-related genes, com-
pared with those with a low alcohol (and high folate)
intake, although the difference was not statistically
significant.
Conclusions
There is substantial and growing evidence of the
mechanisms through which individual dietary and life-
style factors influence cancer pathways and many of
these overlap and interact. In the current review, the
potential underlying mechanisms for the effects of
those concluded by the WCRF/AICR to have strong
(convincing or probable) evidence for a relationship
with CRC risk were discussed, including physical
activity, wholegrains and dietary fibre, red and pro-
cessed meats and body fatness. A number of mecha-
nisms are common to several of these dietary and
lifestyle factors, such as the modulation of inflamma-
tion, the microbiome, genomic stability (e.g. via effects
on DNA damage or repair), insulin resistance and the
regulation of processes (e.g. cell proliferation and
apoptosis) that are vital to the maintenance of large
bowel health. More recently, epigenetic mechanisms,
such as DNA methylation and microRNA expression,
have been implicated in the pathophysiology of can-
cers including CRC, and evidence exists for modula-
tion of the epigenome by environmental and lifestyle
factors such as the intake of dietary fibre and folate.
Better understanding of the mechanisms underlying
the protective effects of dietary and lifestyle factors is
needed to inform more effective interventions for CRC
prevention. Furthermore, stronger evidence, primarily
from human studies and ideally randomised controlled
trials, is required to confirm the findings from observa-
tional studies as well as those performed in vitro and
in animal models, and to provide evidence for the
underlying mechanisms. In the context of the global
spread of Western eating patterns and physical inactiv-
ity, which promote obesity and, in turn, colorectal
carcinogenesis, the need is urgent. However, the com-
plexity of dietary patterns means that studies focusing
on individual nutrients provide only a (small) part of
Figure 2 Alcohol metabolism and mechanisms of alcohol-induced carcinogenesis. Reproduced with permission (Seitz & Stickel 2007). ADH, alcohol dehydro-
genase; ALDH, alcohol dehydrogenase; CYP2E1, cytochrome P450 2E1; NAD+, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinu-
cleotide; ROS, reactive oxygen species. [Colour figure can be viewed at wileyonlinelibrary.com]
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the picture. Future studies that take a more holistic
approach, for example by examining dietary and
overall lifestyle patterns, may be more appropriate for
determining the mechanisms through which lifestyle
influences CRC risk and provide a strong foundation
for the development of effective interventions to delay
or prevent CRC.
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